EXAM: Cabozantinib Doubled Survival in Medullary Thyroid Carcinoma With RET M918T Mutation

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

In this video, Steven I. Sherman, MD, discusses the final overall survival analysis of the EXAM study, a randomized, placebo-controlled phase III trial of cabozantinib in medullary thyroid carcinoma patients.

In this video, Steven I. Sherman, MD, of the MD Anderson Cancer Center in Houston, Texas, discusses the final overall survival analysis of EXAM, a randomized, placebo-controlled phase III trial studying cabozantinib in patients with progressive, locally advanced, or metastatic medullary thyroid carcinoma.

Related Videos
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD, spoke to the potential of ELI-002 2P as a treatment for minimal residual disease positivity in patients with KRAS-mutant solid tumors.
Related Content
After observing a prevalence of thyroid cancer among transgender female patients through clinical observation, a study was prompted by clinicians in order to determine if this is an issue in a larger population.

Thyroid Cancer Rates Are Higher Among Transgender Female Veterans

October 29th 2023
Article

Study shows a high prevalence of thyroid cancer in transgender female patients.

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Oncology On-The-Go Podcast: ASCO 2023 Recap

June 19th 2023
Podcast

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Positive data from a prespecified interim efficacy analysis of the phase 3 LIBRETTO-531 trial support selpercatinib as a potential treatment in advanced, RET-mutant medullary thyroid cancer.

Selpercatinib Elicits Notable PFS Benefit in RET+ Medullary Thyroid Cancer

August 25th 2023
Article

Positive data from a prespecified interim efficacy analysis of the phase 3 LIBRETTO-531 trial support selpercatinib as a potential treatment in advanced, RET-mutant medullary thyroid cancer.

OncView™ Podcast: Advances in Systemic Therapy of Differentiated Thyroid Cancer

OncView™ Podcast: Advances in Systemic Therapy of Differentiated Thyroid Cancer

May 12th 2022
Podcast

In an OncView™ program, Lori Wirth, MD, shared her insights into the current treatment of patients with differentiated thyroid cancer.

Combination therapy with nivolumab and relatlimab produces superior progression-free survival vs nivolumab monotherapy among those with advanced melanoma in the phase 3 RELATIVITY-047 trial.

Nivolumab Combo Yields Sustained Benefit in Advanced Melanoma

June 7th 2023
Article

Combination therapy with nivolumab and relatlimab produces superior progression-free survival vs nivolumab monotherapy among those with advanced melanoma in the phase 3 RELATIVITY-047 trial.

mRNA-4157 plus pembrolizumab appears well tolerated without an increase in immune-mediated adverse effects vs pembrolizumab monotherapy among those with high-risk melanoma in the phase 2 KEYNOTE-942 trial.

mRNA Vaccine/Pembrolizumab Reduces Metastasis/Death Risk in Melanoma

June 7th 2023
Article

mRNA-4157 plus pembrolizumab appears well tolerated without an increase in immune-mediated adverse effects vs pembrolizumab monotherapy among those with high-risk melanoma in the phase 2 KEYNOTE-942 trial.